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ABSTRACT
Background
We previously reported ongoing mutational and isotype switch events in the immunoglobulin (Ig)
heavy chain (H) locus in hairy cell leukemia. Those analyses raised questions on the incidence
and type of selective influences occurring on the tumor B-cell receptor of hairy cell leukemia.
Design and Methods
To further investigate this issue, we examined the full IGH and k and l light chains (IGk and IGl)
variable and constant region transcripts expressed in a large cohort of patients with hairy cell
leukemia (n=88).
Results
Multiple IgH isotypes were expressed in 46/56 (82%) cases of hairy cell leukemia. Comparison
of tumor with normal B-cell repertoires revealed preferential usage of IGHV3-21, IGHV3-30 and
IGHV3-33 in hairy cell leukemia (p=0.001, p=0.003 and p=0.001, respectively). Light chain
analysis demonstrated preferential Igl use with an inverted IGk:IGl ratio (0.7:1) and universal
usage of IGLJ3. Analysis of LCDR3 junctions revealed highly homologous motifs in 40% of IGL.
Parallel analysis of IGH and IGL showed selective pairing of IGHV3-21/30/33 segments to spe-
cific LCDR3-J3 subsets (p=0.008). Of 40 cases of hairy cell leukemia, 38 had mutated IGHV
and/or IGK/LV, with variations in 13/13 cloned cases, while two had 100% unmutated IGHV and
IGK/LV.
Conclusions
Overall, biased IGV usage, preference for Igl with universal IGLJ3 usage and a high incidence of
LCDR3 homologous motifs suggest selective influences on the B-cell receptor of hairy cell
leukemia. Ongoing mutations and isotype switching suggest that influences occur on the tumor
B-cell receptor at ectopic sites.
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Introduction
Hairy cell leukemia (HCL) is a rare, chronic B-cell
neoplasm characterized by leukemic hairy cells present
in blood, bone marrow, and splenic red pulp, with atro-
phy of white pulp. Lymph node involvement is infre-
quent. HCL is typically associated with markers of acti-
vation, which include expression of CD25, CD11c,
FMC7, and CD103 at high intensity.1 A distinctive fea-
ture of HCL is expression of multiple surface (s) immu-
noglobulin (Ig) isotypes, although their prevalence in
HCL has not been fully mapped.1,2
B-cell tumors preserve the B-cell receptor (BCR) fea-
tures of the originally transformed cell.3 Consequently,
immunoglobulin gene (IG) analysis delineates the criti-
cal events of clonal development and defines the IG
heavy (H) and light κ (K) or λ (L) repertoire selected by
specific tumor entities.3 In some instances, IG analysis
may also have prognostic value,3,4 and the selected
IGH/IGL or IGH/IGK pairs can associate with specific
BCR structure and clinical behavior.4 Selective stimuli
to the tumor BCR may be of different types, including
viral or bacterial antigens, or, in germinal center-derived
lymphomas, stromal elements acting on N-glycosylat-
ed residues acquired by somatic mutation.5,6 Analysis of
the selective influences on the tumor BCR has often
been hampered in HCL by the rarity of the disease, and
only small series of cases have been analyzed to date.1
In small series of HCL, we and others have observed
that most HCL carry mutated IGH variable region (V)
genes, with low levels of intraclonal heterogeneity.
Only a minor subset of HCL has unmutated IGHV
genes.2,7-9 Both mutated and unmutated subsets of HCL
express multiple sIgH isotypes with no evidence of
subpopulations.2 Also, activation-induced cytidine-
deaminase is expressed in HCL, and Ig sterile tran-
scripts are produced prior to class switch deletional
recombination.2 However, hairy cells fail to express the
germinal center markers CD38, CD10 and BCL6, or the
memory B-cell marker CD27.10,11 Most importantly,
studies of gene expression profiling of B cells from dis-
crete normal subsets or HCL have shown that hairy
cells are related to memory cells, although with altered
expression of genes controlling cell adhesion and
chemokine-receptors.10 This raises questions on the
incidence of the BCR events and where they occur in
HCL.
The observation that HCL biology may not be sim-
ply recapitulated by normal B-cell physiology raises
several unresolved issues. These include the signifi-
cance of ongoing somatic mutation and isotype switch
events in HCL, and the role of selective influences in
shaping the BCR repertoire of HCL. Here we addressed
these issues by investigating the Ig heavy and light
chains expressed by the tumor cells of a large series of
patients with HCL.
Design and Methods
Patients
Peripheral blood samples were collected from 88
patients with HCL. In all instances, the specimens were
collected at diagnosis before specific therapy. The diag-
nosis of typical HCL and variant HCL was based on
peripheral blood morphology, flow cytometry and
bone marrow immunohistochemistry according to the
World Health Organization classification.12 Informed
consent was obtained in all cases and the study was
approved by the local Institutional Review Board.
Phenotypic analysis
Peripheral blood mononuclear cells were obtained by
Lymphoprep (Nycomed Pharma, Oslo, Norway) gradi-
ent separation. Immunophenotypic studies were car-
ried out on these cells by direct immunofluorescence
techniques with a large panel of antibodies.7 Expression
of CD27, CD38 and sIgH isotypes on HCL was deter-
mined by three-color staining with F(ab’)2 anti-sIgG,
anti-sIgM, anti-sIgD, and anti-sIgA antibodies.7
Expression of sIgκ/λ was determined by three color
staining with fluorescein isothiocyanate (FITC)–conju-
gated F(ab’)2 anti-sIgλ, phycoerythrin (PE)-conjugated
F(ab’)2 anti-sIgκ and peridinin-chlorophyll protein
(PerCP)-conjugated anti-CD20. Previously described
procedures were used to avoid non-specific binding.7
Data were acquired and analyzed and antigen expres-
sion was  defined as described elsewhere.7
Polymerase chian reaction amplification of IGHVDJ,
IGKVJ and IGLVJ transcripts and sequence analysis 
Total RNA was isolated from peripheral blood
mononuclear cells and cDNA prepared as described
previously.7 The full tumor IGHVDJ transcripts were
amplified by PCR with a mixture of Leader-VH-mix
primers and a constant-region primer.7 The full tumor
IGKVDJ or IGLVJ transcripts were identified by PCR
using a mixture of 5’ primers specific for known IGK or
IGL leader sequences (IgKV- or IgLV-leader mix),
together with a 3’ primer specific for either the IGK or
IGL constant-region.13 Amplified products were run on
agarose gel and purified with a Jet Quick Gel extraction
kit (Celbio, Milan, Italy). The tumor IGHVDJ, IGKVJ
and IGLVJ sequences were identified by direct sequenc-
ing and/or after cloning the purified band. Ligation and
cloning were performed with pGEM®-T Easy Vector
System II and JM109 competent cells (Promega, Milan,
Italy). Sequencing was carried out using the v1.1 Big
Dye Terminator Ready Reaction sequencing kit (AB
Applied Biosystems, Applera Italia, Monza, Italy), on
an ABI Prism 310 genetic analyzer (PerkinElmer,
Warrington, UK). Direct sequencing was performed
with the 3’ primer on the constant region and the iden-
tified sequence was confirmed with the family specific
leader 5’ primer, which allowed identification of the
full V-gene transcript. When cloning was performed,
M13 forward and reverse primers were used to
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sequence in both directions. The data were analyzed
using Chromas 1.51 software and aligned to the 2005
updated V-BASE and ImMunoGeneTics (IMGT) data-
bases.14,15
IGHV, IGKV and IGLV gene usage and mutation pat-
terns were analyzed as previously described.7 IMGT
nomenclature was used to assign IG gene use,14 since
this allowed comparison with data from previously
used nomenclatures for IGH, IGK and IGL genes.16,17
Lengths in the IGH and IGK/LCDR3 (HCDR3, KCDR3
and LCDR3, respectively) were calculated according to
IMGT criteria.14 IMGT criteria and nomenclature were
also used for IGHD determination, again allowing com-
parison to segments with other designations from the
literature.14 N-addition of G and C at the joining ends of
the V(D)J junction [(Ngc) Online Supplementary Table S1]
was performed to investigate TdT activity. Recurrent
amino acid sequence motifs in HCDR3, KCDR3 and
LCDR3 were sought using the ClustalW tool (at
http://www.ebi.ac.uk/clustalw/#). Amino acid identity
>60% in the HCDR3 or >80% in the K/LCDR3 was
required for the inclusion of an IgH or an IgK/L chain in
the same subset, respectively.18 Intraclonal heterogene-
ity was assessed in the cloned products and was distin-
guished from Taq infidelity by an increased frequency
compared to Taq error rate and by the finding of the
same mutation in more than one clone.7 If only direct
sequencing was performed, the tumor IGHV, IGKV
and IGLV sequences were confirmed by replicate RT-
PCR and sequencing. The incidence of potential novel
N-glycosylation sites in IGHVDJ, IGKVJ and IGLVJ
transcript sequences was assessed as previously
described.6,19 Statistical analyses were performed using
χ2 or Fisher’s exact tests. p values <0.05 were consid-
ered statistically significant.
Results
Analysis of expressed IGHV region transcripts and
sIgH isotype proteins 
The expressed tumor IGHV sequences were identi-
fied in 83/88 HCL (Online Supplementary Table S1). The
distribution of IGHV families was similar to that of
normal B-cells, but use of individual IGHV gene seg-
ments showed differences from that of the normal B-
cell repertoire (Figure 1A). The IGHV gene segments
most frequently used in HCL were IGHV3-30 (13/83,
16%), IGHV3-33 (9/83, 11%), IGHV3-23 (7/83, 8.5%),
IGHV3-21 (7/83, 8.5%), IGHV4-30/4-31 (5/83, 6%)
and IGHV4-34 (5/83, 6%). Among these segments, the
usage of IGHV3-21, IGHV3-30 and IGHV3-33 was sig-
nificantly increased compared to the normal B-cell
repertoire (p=0.001, p=0.003 and p=0.001, respective-
ly).20 Other IGHV segments were used less frequently
in HCL than in normal B cells (Figure 1A), although the
differences were not statistically significant, for any of
the segments individually, likely due to the number of
cases investigated. However, by combining results of
this study with those of all published HCL IGHV gene
sequences (n=164, Online Supplementary Figure S1A), we
confirmed the overuse of IGHV3-21, IGHV3-30 and
IGHV3-33, and demonstrated the significantly reduced
use of IGHV1-18 (p=0.02) and IGHV3-53 (p=0.02).8,9,21,22
Phenotypic analysis of surface IgM, IgD, IgG and IgA
was performed in 56 HCL (Online Supplementary Table
S1). The majority (46/56, 82%) co-expressed multiple
pre- (IgM±D) and post-switch (IgG±A) isotypes, indi-
cating that multiple isotype expression is a dominant
feature in HCL.2 Of 63 HCL tested, CD38 was negative
in all cases, and the memory B-cell marker CD27 was
negative in 58/63 cases. Interestingly the five CD27-
positive cases (cases HCL8, HCL17, HCL72, HCL82,
and HCL87) differed from all the remaining HCL inves-
tigated, as they had features consistent with the diag-
nosis of variant HCL, including high white blood cell
counts with prolymphocytic morphology and CD25
Figure 1. Expressed IGHV, IGHK and IGLV region repertoire in HCL.
The incidence of IGHV (A), IGKV (B) and IGLV (C) region transcripts
expressed by HCL was compared to the repertoire of normal B
cells from published data.20,24,25 Dark gray columns: HCL; light gray
columns: normal B-cell repertoire. Asterisks indicate V genes
whose incidence was a significantly different between HCL and
the normal B-cell repertoire.
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negativity of the peripheral blood hairy cells.12 These
data confirm that lack of surface CD27 and CD38 is a
feature of typical HCL.11
Analysis of HCDR3 junction
Sixty-nine cases of HCL were evaluable for the
HCDR3 junction (Online Supplementary Table S1 and
Figure 2). IGHD gene segment analysis revealed signif-
icantly increased use of IGHD1 (11/69 cases, 16%) and
IGHD6 (12/69, 17%) families (p=0.001 and 0.02,
respectively). Analysis of specific segments revealed
additional notable biases. In fact, the IGHD1 family
used almost exclusively IGHD1-26 (10/11 cases) and
the IGHD6 family frequently utilized IGHD6-19 (5/12
cases). This observation is remarkable, since neither of
these segments has been reported to be used in normal
B cells.20 In addition, significantly increased selection of
IGHD3-3 (8/69, p=0.00009), IGHD3-9 (4/69, p=0.004),
IGHD3-10 (7/69, p=0.00005) and IGHD4-17 (5/69,
p=0.0009) was also documented. Again, IGHD3-3,
IGHD3-9, and IGHD4-17 are not reportedly selected in
the functional normal B-cell repertoire, and only
IGHD3-10 is restricted to 0.5% of all D segments.20
IGHJ gene segments used in the expressed HCL reper-
toire distributed similarly to those in the normal B-cell
repertoire (Online Supplementary Table S1), HCDR3
length was variable (range 9-28 amino acids, median
16, mean 17), and analysis of recurrent amino acid
sequence motifs could not identify significant simili-
tudes of HCDR3. However, the number of sequences
investigated (n=69) here and the few HCDR3 currently
available in the literature (n=27) preclude any statistical
clustering.8,22,23 Thus, the significance of IGHD biases
remains unresolved as yet.
Analysis of sIgκ and sIgλ protein expression and
IGKV and IGLV region  transcripts 
Seventy of 83 HCL were characterized for sIgκ and
sIgλ protein expression (Online Supplementary Table S1).
Expression of sIgλ was observed in 41/70 (59%) HCL
with an Igκ:Igλ ratio of 0.7:1, indicating preferential
secondary rearrangement of Igλ. The expressed IGK
and IGL tumor transcript sequences were investigated
in 45/70 cases (23 HCL expressing sIgκ and 22 HCL
expressing sIgλ). In two additional samples (HCL30
and HCL33), IGL transcripts from the non-functional
allele were amplified and sequenced. Four HCL (HCL4,
HCL42, HCL70, and HCL83) co-expressing double IGK
or double IGL, or IGK/IGL, were excluded from the
analysis. Among IGKV gene segments (Online
Supplementary Table S2 and Figure 1B), IGKV1D-39
(012/02) was the one most frequently used (6/23, 26%),
and its usage was significantly higher than in normal B-
cells (p=0.03).24 The distal gene segments IGKV1D-17
(case HCL63) and IGKV6D-21 (case HCL11), which are
not reported in the normal B-cell repertoire, were both
used once. The other IGKV segments distributed simi-
larly to normal B-cells.
Among functional IGLV gene segments,  IGLV2-14
was most frequently used (4/22, 18%), followed by
IGLV1-47 (3/22, 14%), IGLV1-40, IGLV1-44, IGLV1-51,
IGLV2-11 and IGLV3-21 (2/22, 9% each) (Online
Supplementary Table S2 and Figure 1C), with an overall
distribution similar to that of the normal B-cell reper-
toire.25
Analysis of KCDR3 and LCDR3 junctions
Twenty-one HCL were evaluable for the KCDR3
junction. IGKJ genes were used by HCL in a fashion
similar to that in the normal B-cell repertoire (Online
Supplementary Table S2).24 KCDR3 length ranged from 7
to 11 amino acids (median 9) and 11/21 KCDR3 had
identical pI (range 6.5-13, median 13). Overall analysis
of KCDR3 amino acid sequences reflected pI similari-
ties and identified three subsets, all with 88.8%
sequence identity (Online Supplementary Table S2).
Subset 1K (HCL28 and HCL2) harbored IGKV1D-33-
J1/4 rearrangements (QQYDNLP[L/R]T), which associ-
ated with IGHV3-23 (HCL28) or IGHV1-02 (HCL2).
Subset 2K (HCL7/330 and HCL67) harbored IGKV3-
20-J1/2 rearrangements (QQYGRSP[Q/Y]T), which
associated with IGHV2-05 (HCL7/330) or IGHV4-34
(HCL67). Subset 3K (HCL19 and HCL63) harbored
IGKV1-17/1D-17-J1/2 rearrangements
(LQHNSYP[R/Y]T), which associated with IgHV3-21
(HCL19) or IgHV4-34 (HCL63).
Twenty-two HCL were evaluable for the functional
LCDR3 junction. Remarkably, among IGLJ segments,
virtually all cases used IGLJ3 (21/22, 95.5%) (Online
Supplementary Table S2 and Figure 3). The universal use
of IGLJ3 was higher than expected by chance alone
(50%), and significantly higher than its frequency
(34%) in normal B cells (p=0.000000001).26 Remarkably,
2/2 HCL with non-functional LCDR3 junctions (HCL30
and HCL33) failed to use IGLJ3, further indicating strik-
ingly selective influences on the functional repertoire.
In particular, HCL30 used IGLJ1 with a TAG stop at
joining codon 115, whereas HCL33 used IGLJ6 with
and out-of-frame rearrangement in codon 115 (Online
Supplementary  Table S2). LCDR3 length ranged from 9
to 13 amino acids (median 11) and the pI ranged from
4.4 to 13 (median 13), with 13/22 LCDR3 having an
Figure 2. Expressed IGHD families in HCL. Incidences of IGD fam-
ilies expressed by HCL were compared to the repertoire of normal
B-cells from published data.20 Dark gray columns: HCL; light gray
columns: normal B-cell repertoire. Asterisks indicate regions with
identified significant differences between HCL and the normal B-
cell repertoire. The D1 family was represented by D1-26 in 10/11
cases. The D6 family was represented by D6-19 in 5/12 cases.
D1-26 and D6-19 are not reportedly used by normal B cells.20
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identical pI. 
Analysis of LCDR3 amino acid sequences identified
three HCL subsets (Figure 4). Subset 1L (HCL35,
HCL22, HCL44, HCL49, and HCL40) harbored IGLV1-
44/47-J3 rearrangements with ≥85% homologous
LCDR3 (Figure 4). Of note, these HCL paired only with
the highly identical IGH3-30 or IGHV3-33 segments in
four out of five cases, the exception being case HCL22,
which used IGHV3-21. Remarkably, the selective clus-
tering of IGHV3-21/30/33 segments (5/5, 100%) within
this subset was significant, when compared to pairing
of IGHV3-21/30/33 segments with the remaining
CDR3 investigated for IGLV-J (8/17, 47%, p=0.03) or
the total IGL/KV-J (13/38, 34%, p=0.005) rearrange-
ments (Online Supplementary Table S2). Subset 2L
(HCL27 and HCL32) harbored IGLV3-21-J3 rearrange-
ments with 91% homologous LCDR3 (QVWDSSS-
DH[W/V]V), and associated with either IGHV3-30 or
IGHV3-23. Subset 3L (HCL64 and HCL23) harbored
IGLV1-40-J3 rearrangements with 81.8% homologous
LCD3 (QSYD[S/N]SL[SG/TR]SGV), and associated
with IGHV4-34 or IGHV3-21. Overall, the overused
IGHV3-30, IGHV3-33 and IGHV-3-21 genes clustered
within the identified LCDR3 sets (7/9 cases; 78%), and
not with the CDR3 from the remaining IGK/LV-J
rearrangements investigated (9/34, 26%, p=0.008).
Together with Igλ light chain preference and universal
IGLJ3 use, these data further suggest that selection
events are dominant in the Igλ light chain of HCL. TdT
activity was absent in almost 50% light chain
rearrangements (20/41 light chain junctions). Since TdT
activity decreases during B-cell ontogeny,27 lack of N-
addition/deletion of G and C at the ends of V-J junction
(Online Supplementary Table S2) is suggestive of rear-
rangements having occurred late (in the periphery) as a
result of receptor revision in the light chain, after
downregulation of the TdT enzyme.14
Somatic mutation analysis of IGHV, IGKV and IGLV
The mutation status of IGHV tumor transcripts was
evaluated in 83 HCL (Online Supplementary Table S1).
Overall, IGHV genes carried variable tiers of mutations
(range 80.95-100%; median 96.56%, mean 95.97%).
Three of 83 HCL had completely unmutated IGHV
genes (100% homology to germline). However, by
using the arbitrary 2% cut-off that defines mutational
status in other lymphoproliferative disorders and that is
being used for clinical correlates in ongoing clinical
studies,28 the unmutated HCL subgroup expanded to
17/83 HCL (20.5%). 
The distribution of individual IGHV genes varied
among mutated and unmutated cases of HCL (Online
Supplementary Table S2 and Figure 5A). In particular,
IGHV3-30, the segment most frequently used in HCL,
showed a selective tendency to distribute in unmutated
rather than mutated HCL cases (6/17, 35%  unmutated
HCL vs. 7/66, 10% mutated HCL, p=0.01). IGHV4-34
was also more frequently used in unmutated HCL
(3/17, 18%) than in mutated cases (2/66, 3%) (p=0.02).
IGKV mutation status (n=23) (Online Supplementary
Table S2 and Figure 5B) was variable (homology range
93.61%-100%, median 97.26%, mean 97.31%), and
2/23 cases had completely unmutated IGKV genes.
Using the arbitrary 2% cut-off value, 9/23 (39.1%)
IGKV were considered unmutated. IGLV mutation sta-
tus was evaluable in 22 cases with functional IGLV
rearrangements (Online Supplementary Table S2 and
Figure 5C). IGLV homology to germline ranged from
89.9% to 100% (median 97.12%, mean 96.83%), and
1/22 HCL had completely unmutated IGLV genes.
Using the arbitrary 2% cut-off, 8/22 (36.4%) IGLV were
unmutated.
Parallel assessment of IGHV and IGKV/IGLV muta-
tion status was feasible in 40 cases of HCL (Online
Supplementary Table S2). The IGHV-IGKV/IGLV muta-
tion status was concordant in 22/40 HCL. Eighteen
cases were mutated in both IGHV and IGKV/IGLV.
Figure 3. IGLJ segment usage in IGλ HCL. The incidence of IgLJ
segments in the functional IGLVJ transcripts expressed by HCL
was compared to the functional repertoire of normal B cells from
published data.26 Dark gray columns: HCL; light gray columns: nor-
mal B-cell repertoire. *IGLJ3 segment use in HCL was universal
(>95% cases) and significantly superior to IGLJ3 use in normal B
cells.
Figure 4. Subsets of highly similar LCDR3 in HCL. Amino acid
sequences are shown for all HCL cases within a LCDR3 subset.
The rearranged IGLV and IGLJ and the associated IGHV gene seg-
ment are indicated together with the amino acid sequence of
each case. Amino acid homology to the first LCDR3 from each
subset is indicated by dots. HCL belonging to these subsets pref-
erentially utilized the most frequent IGHV3-21, 3-30 or 3-33 gene
segments. (*, **, ***): *selective distribution of IGHV3-21, 3-30 or
3-33 in HCL from subset 1L compared to Igλ-positive HCL not
belonging to subset 1L; **selective distribution of IGHV3-21, 3-30
or 3-33 in HCL from subset 1L compared to Igλ-positive or Igκ-pos-
itive HCL with light chain CDR3 not belonging to subset 1L;
***selective distribution of IGHV3-21, 3-30 or 3-33 in HCL from
subsets 1L, 2L and 3L compared to HCL with light chain CDR3 not
belonging to these subsets. ^An identical LCDR3 was reported in
2/368 normal or autoreactive B cells (0.5%), with no indication of
antigen reactivity. °Identical LCDR3 in 5/368 normal or autoreac-
tive B-cells (1.3%), that identified anti-platelet αIIbβ3 integrin
(EBA11) or anti-La (SS-B)SLE autoantibodies.46
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Four were unmutated in both IGHV and IGKV/IGLV.
Of these, two cases displayed both IGHV and
IGKV/IGLV rearrangements with a 100% homology to
closest germline, confirming the existence of a very
minor subset of HCL with completely unmutated IG
genes.2
The IGHV-IGKV/IGLV mutation status appeared dis-
cordant in 18 cases of HCL (12 IGHV mutated-
IGKV/IGLV unmutated cases and six IGHV unmutat-
ed-IGKV/IGLV mutated cases). However, 16/18 discor-
dant cases carried some level of mutation (homology to
germline <100%) in both IGHV and IGKV/IGLV, sug-
gesting that the variations likely represent true muta-
tions and not polymorphisms.29 Only two discordant
cases (HCL37 and HCL81) carried heavily mutated
IGHV (94.79% homology) or IGKV (94.98%) genes
coupled to completely unmutated (100%) IGKV or
IGHV genes, respectively. These two particular cases
might be representative of an antigen experienced BCR
(with mutated IGH or IGK) rescued after secondary
recombination of the IGK or IGH chain on the second
allele, and suppression of the first functionally
rearranged allele (receptor revision).30,31
Analysis of intraclonal heterogeneity of IGHV, IGKV
and IGLV
Cloning and sequencing of IGHV and IGKV or IGLV
transcripts was performed in 12 cases of HCL (Table 1).
In all cases, cloning confirmed the results of direct
sequencing. Cloning of IGHV transcripts revealed intr-
aclonal variations within the same or different tumor
isotypes in 11/12 cases, including 2/2 cases with >98%
and <100% IGHV homology to germline (cases HCL7
and HCL35). Cloning of the paired IGK/L tumor
sequence confirmed intraclonal variations in the light
chain of the same 11/12 cases. Using stringent criteria
for ongoing activity (i.e. ≥2 identical variations repeat-
ed in separate clones), intraclonal heterogeneity was
restricted to 3/11 cases. Lack of repetitions in the
remaining 8/11 cases may be due to the mutational fre-
quencies in the light chain genes, which, in normal
individuals, are generally lower than in the IGHV
genes.32 Only HCL38, having both IGHV and IGLV
genes with 100% homology to germline, did not dis-
play intraclonal mutations in either IGHV or IGLV
genes. 
Discussion
Our immunogenetic analysis of the expressed IGH
and IGK/L repertoire in a large cohort of patients has
implications for the origin of HCL, and indicates that
IG selection may play an important role in the patho-
genesis of this disease. IGHV analysis shows that HCL
is characterized by biased usage of IGHV3-21, IGHV3-
30 and IGHV3-33, in agreement with prior analyses on
smaller HCL groups.9,21 IGHV3-30 and IGHV3-33 are
highly homologous segments with a single amino acid
difference in the CDR2, are recognized by the same
anti-CDR1 (B6) monoclonal antibody, and thus may
share the ability to bind identical antigens.33 Indeed,
IgHV3 family members, including IGHV3-30 and
IGHV3-33, react with common bacterial superantigens,
such as modified staphylococcal protein A,34 or with
the natural staphylococcal enterotoxin A, which is suf-
ficient to induce survival of IGHV3-expressing B cells
by low-affinity binding.35 Furthermore, IGHV3-30 is
reportedly involved in the immune response against
Toxoplasma infection, providing additional clues to
potential antigens sustaining HCL.36 Clearly, the selec-
tive influences active in HCL appear to follow routes
that are different from those of other B-cell neoplasms,
in particular from the extensively investigated IgM-
positive chronic lymphocytic leukemia (CLL).19 For
example, IGHV1-69 was totally absent in HCL from
Figure 5. Distribution of mutated and unmutated IGHV (A), IGKV
(B) and IGLV (C) segments in HCL. Incidence of tumor IGHV, IGKV
and IGLV with homology to germline inferior (mutated) or superi-
or (unmutated) to 98% in HCL. Segments with <98% homology
are indicated by dark gray columns; segments with >98% homol-
ogy to germline are indicated by light gray columns. Asterisks indi-
cate segments with significantly different distribution between
mutated and unmutated cases of HCL.
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our and previously published series (total 164 IgHV
sequences),2,7,8,21,22,37 while it dominates the unmutated
subset in CLL (Online Supplementary Figures S1A and
S1B).19 Similarly, IGHV4-34 is used predominantly in a
mutated conformation by CLL, but was preferentially
unmutated in the HCL cases in our series (Figure 5A),
and even more significantly when all published HCL
sequences were pooled (p=0.0002).2,7,8,21,22,37 Lack of
apparent HCDR3 stereotypy in HCL is another feature
of variance with CLL, which, conversely, frequently
groups cases with shared HCDR3 structural fea-
tures.4,18,38 This also indicates that antigen drive may not
rely on HCDR3-mediated interactions in HCL. Con-
versely, the low mutational rate of IGHV genes
expressed in HCL, particularly of IGHV3-30 and
IGHV3-33 segments, which represent almost 50% of
all unmutated HCL, suggests that selective influences
may be related to the IGHV segment itself.34,35
Analysis of Ig light chains provides novel evidence
that HCL is characterized by selection events in the
tumor BCR. In fact, HCL display: (i) an inverted Igκ:Igλ
ratio (0.7:1); (ii) universal usage of IGLJ3 in the func-
tional sIgλ expressors; and (iii) subsets with highly
homologous KCDR3 and LCDR3. The preferential
usage of Igλ light chain in our large series is consistent
with prior independent studies,39-42 and can be consid-
ered a unique feature of HCL. In the normal B-cell
repertoire and in other B-cell neoplasms, Igκ is the most
frequently used light chain.43-48 On these bases, our
results suggest that HCL requires selective usage of Igλ.
The functional implications of Igλ selection in HCL
remain speculative. The observations that (i) almost
50% HCL expressing sIgλ utilize IgHV3-21, IgHV3-30
or IgHV3-33 only; ii) virtually all HCL expressing Igλ
utilize IgLJ3; and (iii) 40% HCL expressing Igλ display
LCDR3 sets with shared structural features, suggest
that HCL expressing Igλ may recognize common anti-
gens requiring homologous LCDR3-J3 stretches. 
LCDR3 identical motifs were documented within
IGHV3-21, IGHV3-30 or IGHV3-21 HCL (Table 1). In
public databases of normal or autoreactive B-cells, we
identified motifs identical to LCDR3 from HCL sets 1L
or 2L, although specific antigen reactivities were found
only in set L2.46 The molecular triggers of the Igλ bias
and LCDR3-J3 selection in HCL are unknown. One
possibility of IgL selection is that the Igκ-to-Igλ shift
may derive from secondary rearrangements with res-
cue of a new light chain in the periphery. Secondary
rearrangements of Igλ after Igκ deletion have been
observed in cases of Igλ-positive B-cell neoplasms.45-47,49
The observation of absent Ngc incorporations due to
absent TdT activity in almost 50% HCL light chain
rearrangements favors the hypothesis that secondary
rearrangements occur in the periphery.27 We have
observed the potential ability of HCL to revise light
chains in cases co-expressing mutated double light
chain transcripts and/or protein with peripheral up-reg-
ulation of RAG-1.50 Also, double productive and func-
tional Ig light chain expression has been described in
one independent case of HCL and is putatively the con-
sequence of peripheral receptor revision.51
Classically, mutational status of IGHV genes distin-
guishes whether the B-cell has encountered antigen in
the germinal center with a T-cell-dependent reaction or
whether it derives from antigen-naïve B cells.7
However, there is evidence that the BCR can also inter-
act with antigen in a T-independent pathway and accu-
mulate a low level of somatic mutations ectopically,
likely in the marginal zones.21,52 Several observations
from both Ig heavy and light chain rearrangements
indicate that HCL cells have experienced antigen stim-
ulation. First, the majority of HCL are characterized by
somatic mutations. Second, cloning of IGV region tran-
scripts confirms the existence of low levels of intraclon-
al heterogeneity also in cases with 98% ≤ homology
<100% to germline.19 Third, the vast majority (82%) of
HCL co-express multiple pre-switch (IgM±D) and post-
switch (IgG±A) sIgH, independently of mutational sta-
tus and while activation-induced cytidine deaminase is
expressed.2 Histological findings and lack of CD27 and
CD38 suggest that, in typical HCL, the mutational and
switch events are unlikely to occur in the germinal cen-
Table 1. Intraclonal variability in hairy cell leukemia.
Code* IGHV Homology Intraclonal IGK/LV Homology Tumor/total IGL Intraclonal
(%) heterogeneity in (%) heterogenity in IGK/LV
in IGHV
Unique Repeats
HCL9 3-07 92.45 + KV1-D39(012/02) 97.49 11/11 3 0
HCL25/206 3-23 91.31 + KV3-11(L6) 97.13 6/11 1 0
HCL7/330 2-05 98.96 + KV3-20(A27) 96.90 9/12 3 0
HCL35 3-30 98.49 + LV1-44(1c) 97.16 4/12 4 1
HCL44/42 3-33 93.50 + LV1-47(1g) 94.68 7/7 2 0
HCL40 3-30 97.61 + LV1-47(1g) 98.93 11/12 2 0
HCL38/283 3-30 100.00 - LV2-11(2e) 100.00 10/10 0 0
HCL3/266 1-02 96.18 + LV2-14(2a2) 95.43 4/12 0 2
HCL68 4-39 93.84 + LV2-8(2c) 96.84 8/8 5 2
HCL27 3-23 96.52 + LV3-21(3h) 98.18 9/11 3 0
HCL32 3-30 95.83 + LV3-21(3h) 96.01 7/12 4 0
HCL26/216 3-23 91.66 + LV4-69(4b) 95.87 11/11 4 0
Intraclonal heterogeneity in the cloned IgHV products was defined positive when the same mutation was present in more than one clone from different isotype
transcripts.2,7,29 *The HCL cases with previously published details on intraclonal variation in tumor IgH isotypes are listed with the original code after the slash.2,7,29
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ter.11 Additionally, in the present large series of HCL,
we observed an irrelevant incidence of novel N-glyco-
sylation sites introduced by somatic mutation in the
tumor IgV region (<6%), similar to that observed in
normal memory B cells or in transformed memory and
marginal zone B cells (Online Supplementary Tables S1
and S2).5,6,19,53 Since N-glycosylation sites are specifically
introduced in the IgV region of germinal center-derived
lymphomas, while they are rare in marginal zone or
post-germinal center B-cell neoplasms,5,6,19,53 our results
provide further support to the hypothesis that HCL
originates from non-germinal center derived B cells.
CD27-negative memory B cells or marginal zone B
cells are the candidate counterparts of HCL.54
Comparison of the gene expression profiles of 14 HCL
with the profiles of normal B cells from the naïve, ger-
minal center, memory and plasma cell compartments
showed that hairy cells were related to memory B
cells.10 However, the data were limited by the unavail-
ability of a marginal zone B-cell compartment.1,10
Indeed, HCL and marginal zone B cells share several
immunogenetic features, including variable tiers of
IGHV mutations, evidence of ongoing somatic hyper-
mutation and lack of novel N-glycosylation sites.19,36,55
The morphology and phenotype of hairy cells also
resemble those of marginal zone-derived CD23-nega-
tive, CD27-negative, CD38-negative interfollicular B
cells. Overall, efforts should be directed at identifying
the normal counterpart within these categories.1,36,55
Knowledge of IGV gene use in these B-cell populations
will be informative and perhaps more relevant when
available from both normal and transformed B-cells.
In conclusion, the present largest immunogenetic sur-
vey identifies the IG repertoire selected in HCL. The
remarkable preference for Igλ with universal IGLJ3 use
and a high incidence of LCDR3 homologous motifs fur-
ther clarifies the selective influences present in the BCR
of HCL. Whether this distribution of repertoire in HCL
reflects that of a postulated normal B-cell counterpart
remains to be clarified, and may follow from a more
accurate characterization of normal B-cell subsets. 
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